Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 : Th2 cytokine ratios
Authors:
- Kayhan T Nouri-AriaKNKayhan T Nouri-Aria
- Duncan R WilsonDWDuncan R Wilson
- Samantha M WalkerSWSamantha M Walker
- Adrienne VerhoefAVAdrienne Verhoef
- Stephen J TillSTStephen J Till
- Stephen R DurhamSDStephen R Durham
- 1 January 2002
- journal article
- clinical trial
- Published by Wiley in Immunology
- Vol. 105 (1) , 56-62
Abstract
Summary: Grass pollen immunotherapy is the only treatment for hayfever that is both effective and confers long‐term benefit. Immunotherapy may act by altering the local nasal mucosal T helper type 2 (Th2) to type 1 (Th1) cytokine balance either by down‐regulation and/or immune deviation of T‐lymphocyte responses. There is controversy as to whether these changes are detectable in peripheral blood. We therefore examined both local nasal and peripheral T‐cell responses to allergen exposure in the same subjects before and after immunotherapy. In a double‐blind trial of grass pollen immunotherapy, nasal biopsies were obtained at baseline and during the peak pollen season following 2 years of immunotherapy. Placebo‐treated patients showed a seasonal increase in CD3+ T cells (P = 0·02) and in interleukin‐5 (IL‐5) mRNA+ cells (P = 0·03) and no change in interferon‐γ (IFN‐γ ) mRNA+ cells (P = 0·2) in the nasal mucosa. In contrast, in the immunotherapy‐treated group, there were no changes in the number of CD3+ T cells (P = 0·3) and IL‐5 mRNA+ cells (P = 0·2) but a significant increase in the number of IFN‐γ mRNA+ cells (P = 0·03). Furthermore, clinical improvement in the immunotherapy‐treated group was accompanied by a seasonal increase in the ratio of IFN‐γ to IL‐5 mRNA+ cells in the nasal mucosa (P = 0·03). In contrast, there were no significant changes in peripheral T‐cell proliferative responses or cytokine production for IFN‐γ or IL‐5 in response to grass pollen either within or between the two treatment groups. We conclude that successful grass pollen immunotherapy was associated with an increase in the ratio of IFN‐γ to IL‐5 mRNA+ cells in the nasal mucosa, whereas these changes were not reflected by alterations in peripheral blood T‐cell proliferative responses or cytokine production before/after treatment.Keywords
This publication has 45 references indexed in Scilit:
- Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trialJournal of Allergy and Clinical Immunology, 2001
- Role of interleukin 10 in specific immunotherapy.Journal of Clinical Investigation, 1998
- Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapyJournal of Allergy and Clinical Immunology, 1997
- Changes in Allergic Inflammation Associated with Successful ImmunotherapyInternational Archives of Allergy and Immunology, 1995
- Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthmaJournal of Allergy and Clinical Immunology, 1993
- Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.Journal of Clinical Investigation, 1993
- Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavityJournal of Allergy and Clinical Immunology, 1991
- Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1991
- Changes in nasal metachromatic cells during allergen immunotherapyClinical & Experimental Allergy, 1991
- IgG Subclass Antibody Response in Grass Pollen‐Allergic Patients Undergoing Specific ImmunotherapyAllergy, 1984